Other relevant news · Page 12 · Mind Medicine Australia
Mind Medicine Australia logo
Donate

Other relevant news

Stroke victims to be given psychedelic drug DMT in groundbreaking study

Metro, February 4, 2021

Psychedelic medicine DMT could help stroke victims recover by rewiring their brains faster, according to the first clinical trial of its kind.

Psychedelics as Antidepressants

Scientific American, January 30, 2021

The treatments of the future may arise from a long-stigmatized class of medicines.

How ecstasy and psilocybin are shaking up psychiatry

Nature, January 27, 2021

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.

Ketamine to treat depression and addiction at UK’s first medical psychedelic psychotherapy clinic

iNews, January 25, 2021

The medicine is to be used by Awakn Life Sciences when its centre opens in Bristol in March, explains its chief medical officer Dr Ben Sessa.

Unique magic mushroom microdosing study to begin in Australia

New Atlas, January 20, 2021

A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics. The research promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging technique and a unique kind of trial protocol.

EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization

Forbes, January 15, 2021

A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.

Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO

CNBC, January 15, 2021

Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

Global News Wire, January 8, 2021

COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States.

Mount Sinai Health System Launches Center for Psychedelic Research

Psychedelic Finance, January 8, 2021

The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multi-pronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.

Why Investors Are Psyched About Psychedelic Stocks

Visual Capitalist, January 7, 2021

Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.

Health care professionals okayed to use magic mushrooms for training in psilocybin therapy

Now Toronto, December 9, 2020

Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.

Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.

The Age, December 8, 2020

Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.

Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s

Parkinson's News Today, December 4, 2020

Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.

United Nations approves WHO recommendation to reschedule cannabis in historic vote

Marijuana Business Daily, December 2, 2020

The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

Jewish psychedelics advocate working to turn drug into legal medicine

The Jerusalem Post, November 20, 2020

In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.

‘The war on drugs failed’: California lawmaker will push to decriminalise psychedelics

The Guardian, November 20, 2020

A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.

Psilocybin for Depression Study Approved and Funded by German Government

Psilocybin Alpha, November 19, 2020

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

Canada Is Allowing People With Depression to Do Psychedelic Mushrooms

Vice World News, November 17, 2020

The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.

What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD

The Dales Report, November 11, 2020

The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.

Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’

CNBC, November 4, 2020

Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×